載體指南
相關(guān)服務(wù)
載體構(gòu)建質(zhì)粒DNA制備
病毒包裝服務(wù)
mRNA基因遞送解決方案
CRISPR基因編輯解決方案
shRNA基因敲低解決方案
哺乳動(dòng)物shRNA表達(dá)慢病毒載體
慢病毒shRNA干擾載體系統(tǒng)是一種非常高效的,能穩(wěn)定干擾各種哺乳動(dòng)物細(xì)胞靶基因表達(dá)的載體工具。一旦病毒基因組被逆轉(zhuǎn)錄成DNA并永久整合到宿主細(xì)胞基因組中,由人類U6啟動(dòng)子驅(qū)動(dòng)表達(dá)的shRNA將會(huì)導(dǎo)致靶基因mRNA的降解。與合成siRNA相比,慢病毒干擾具有明顯的優(yōu)勢(shì)(見(jiàn)下文載體優(yōu)勢(shì))。
通過(guò)改造優(yōu)化,我們的慢病毒載體刪除了與病毒包裝和轉(zhuǎn)導(dǎo)相關(guān)的基因(這些基因由輔助質(zhì)粒進(jìn)行表達(dá),用于病毒包裝過(guò)程),使產(chǎn)生的慢病毒顆粒是復(fù)制缺陷型的。即包裝的病毒只具有轉(zhuǎn)導(dǎo)靶細(xì)胞的能力,而無(wú)法在靶細(xì)胞中進(jìn)行大量復(fù)制,因而具有很高的生物安全性。
更多信息請(qǐng)查閱“慢病毒基因表達(dá)載體”,關(guān)于慢病毒shRNA干擾載體的更多信息,請(qǐng)參考以下文獻(xiàn)。
參考文獻(xiàn) | 主題 |
---|---|
RNA. 9:493-501 (2003) | Development of lentiviral shRNA vectors |
亮點(diǎn)
我們的慢病毒shRNA干擾載體采用的是第三代慢病毒包裝載體系統(tǒng)。經(jīng)優(yōu)化,該載體在大腸桿菌體內(nèi)具有很高的拷貝數(shù),包裝的活病毒具有很高的滴度,對(duì)大多數(shù)宿主細(xì)胞具有高效的轉(zhuǎn)導(dǎo)能力,能有效地把載體整合到靶細(xì)胞基因組。人類U6啟動(dòng)子能夠驅(qū)動(dòng)shRNA的高水平轉(zhuǎn)錄,同時(shí),我們經(jīng)過(guò)優(yōu)化的shRNA莖-環(huán)序列可高效形成有效的干擾RNA。
我們的U6 shRNA慢病毒載體經(jīng)過(guò)基因敲低效率驗(yàn)證,結(jié)果如下圖所示。結(jié)果展現(xiàn)了U6 shRNA與miR30 shRNA之間的敲低效率比較。
圖1 U6 shRNA慢病毒載體與miR30 shRNA慢病毒載體對(duì)EGFP的敲低效率比較。(A)U6啟動(dòng)子驅(qū)動(dòng)的shRNA表達(dá)的慢病毒載體與miR30 shRNA(4條shRNA)慢病毒載體分別包裝成慢病毒,然后轉(zhuǎn)導(dǎo)穩(wěn)定表達(dá)EGFP的HEK293T細(xì)胞。藥篩前后流式細(xì)胞術(shù)檢測(cè)EGFP表達(dá)情況。(B)藥篩前,EGFP表達(dá)在U6 shRNA的作用下減少了46%(P<0.001),在CMV啟動(dòng)子驅(qū)動(dòng)表達(dá)的miR30 shRNA(單shRNA)作用下減少了13%(P<0.001),在CMV啟動(dòng)子驅(qū)動(dòng)表達(dá)的miR30 shRNA(4條shRNA)作用下減少了44%(P<0.001)。(C)EGFP表達(dá)在U6 shRNA的作用下減少了72%(P<0.001),在CMV啟動(dòng)子驅(qū)動(dòng)表達(dá)的miR30 shRNA(單shRNA)作用下減少了60%(P<0.001),在CMV啟動(dòng)子驅(qū)動(dòng)表達(dá)的miR30 shRNA(4條shRNA)作用下減少了67%(P<0.001)。EGFP的相對(duì)表達(dá)量通過(guò)轉(zhuǎn)導(dǎo)與未轉(zhuǎn)導(dǎo)細(xì)胞的熒光強(qiáng)度中值(Median fluorescence intensities,MFI)的比值計(jì)算。三次重復(fù)實(shí)驗(yàn),圖中顯示SD值,p值根據(jù)Tukey檢驗(yàn)計(jì)算。
永久性干擾:慢病毒整合到宿主細(xì)胞基因組是一個(gè)不可逆的過(guò)程,U6啟動(dòng)子能驅(qū)動(dòng)shRNA的組成型表達(dá),對(duì)于靶基因的干擾通常是穩(wěn)定和永久的。 基于這個(gè)優(yōu)勢(shì),可對(duì)培養(yǎng)細(xì)胞或活體干擾表型進(jìn)行長(zhǎng)期分析,有助于分離具有不同干擾水平和/或不同表型的克?。划?dāng)干擾載體攜帶熒光標(biāo)記如EGFP時(shí),可通過(guò)流式分選具有不同熒光強(qiáng)度(熒光強(qiáng)度和整合數(shù)量有關(guān),進(jìn)而與干擾程度有關(guān))的細(xì)胞。
滴度高:我們的病毒載體可以包裝出高滴度的病毒。我們提供的病毒包裝服務(wù),病毒滴度可以達(dá)到>109 TU/ml。在這樣的病毒滴度下,如果選擇合適的劑量去轉(zhuǎn)導(dǎo)體外培養(yǎng)的哺乳動(dòng)物細(xì)胞,則轉(zhuǎn)導(dǎo)效率可接近100%。
宿主范圍廣泛:我們的病毒包裝系統(tǒng)包裝出來(lái)的病毒含有VSV-G包膜蛋白,此蛋白擁有非常廣泛的親和性,可以轉(zhuǎn)導(dǎo)幾乎所有的哺乳動(dòng)物細(xì)胞,包括分裂細(xì)胞,非分裂細(xì)胞,原代細(xì)胞,穩(wěn)定細(xì)胞系,干細(xì)胞,分化細(xì)胞,貼壁細(xì)胞和懸浮細(xì)胞等各類哺乳動(dòng)物細(xì)胞,甚至還可以轉(zhuǎn)導(dǎo)一些非哺乳動(dòng)物細(xì)胞。使用傳統(tǒng)的轉(zhuǎn)染方式轉(zhuǎn)導(dǎo)神經(jīng)元細(xì)胞是非常難的,但是采用我們慢病毒載體系統(tǒng)可以輕易的實(shí)現(xiàn)神經(jīng)元細(xì)胞的轉(zhuǎn)導(dǎo)。相對(duì)于在某些細(xì)胞中具有較低轉(zhuǎn)導(dǎo)效率的腺病毒和不能用于非分裂細(xì)胞的逆轉(zhuǎn)錄病毒而言,利用我們的慢病毒包裝系統(tǒng)包裝出來(lái)的病毒具有廣泛的親和性。
基因拷貝數(shù)相對(duì)均一:通常情況下,采用病毒轉(zhuǎn)導(dǎo)的方式可以比較均一的將外源基因轉(zhuǎn)入靶細(xì)胞中,而傳統(tǒng)的質(zhì)粒轉(zhuǎn)染則呈現(xiàn)出較高的不均一性,導(dǎo)致某些細(xì)胞會(huì)獲得較多拷貝質(zhì)粒而某些則會(huì)獲得較少甚至完全沒(méi)有。
體內(nèi)外實(shí)驗(yàn)均有效:我們的載體不僅擁有良好的體外細(xì)胞轉(zhuǎn)導(dǎo)能力,同樣適用于體內(nèi)活體動(dòng)物實(shí)驗(yàn)。
安全性:我們的病毒載體系統(tǒng)具備了以下兩大特點(diǎn),因而具有非常高的安全性。一、病毒包裝和轉(zhuǎn)導(dǎo)所必需的基因由三個(gè)輔助質(zhì)粒分開(kāi)表達(dá)。二、5' LTR的啟動(dòng)子自失活。因此,在進(jìn)行病毒包裝和病毒轉(zhuǎn)導(dǎo)的時(shí)候不會(huì)產(chǎn)生具有復(fù)制能力的病毒顆粒,使用我們的載體對(duì)人體的健康威脅也是最低的。
不足之處
技術(shù)復(fù)雜:使用慢病毒載體時(shí),需要在包裝細(xì)胞中產(chǎn)生活病毒,然后測(cè)定病毒滴度。因此慢病毒轉(zhuǎn)染相對(duì)于常規(guī)質(zhì)粒轉(zhuǎn)染,技術(shù)難度更高,周期更長(zhǎng)
永久性干擾:慢病毒整合到宿主細(xì)胞基因組是一個(gè)不可逆的過(guò)程,U6啟動(dòng)子能驅(qū)動(dòng)shRNA的組成型表達(dá),對(duì)于靶基因的干擾通常是穩(wěn)定和永久的。 一旦慢病毒shRNA干擾載體對(duì)基因產(chǎn)生了干擾,目的基因的表達(dá)就很難被重新激活。 根據(jù)不同的實(shí)驗(yàn)?zāi)康模@有可能是優(yōu)勢(shì)也可能是劣勢(shì)。
載體關(guān)鍵元件
RSV promoter: Rous sarcoma virus promoter. It drives transcription of viral RNA in packaging cells. This RNA is then packaged into live virus.
Δ5' LTR: A deleted version of the HIV-1 5' long terminal repeat. In wildtype lentivirus, 5' LTR and 3' LTR are essentially identical in sequence. They reside on two ends of the viral genome and point in the same direction. Upon viral integration, the 3' LTR sequence is copied onto the 5' LTR. The LTRs carry both promoter and polyadenylation function, such that in wildtype virus, the 5' LTR acts as a promoter to drive the transcription of the viral genome, while the 3' LTR acts as a polyadenylation signal to terminate the upstream transcript. On our vector, Δ5' LTR is deleted for a region that is required for the LTR's promoter activity normally facilitated by the viral transcription factor Tat. This does not affect the production of viral RNA during packaging because the promoter function is supplemented by the RSV promoter engineered upstream of Δ5' LTR.
Ψ: HIV-1 packaging signal required for the packaging of viral RNA into virus.
RRE: HIV-1 Rev response element. It allows the nuclear export of viral RNA by the viral Rev protein during viral packaging.
cPPT: HIV-1 Central polypurine tract. It creates a "DNA flap" that increases nuclear importation of the viral genome during target cell infection. This improves vector integration into the host genome, resulting in higher transduction efficiency.
U6 Promoter: Drives expression of the shRNA. This is the promoter of the human U6 snRNA gene, an RNA polymerase III promoter which efficiently expresses short RNAs.
Sense, Antisense: These sequences are derived from your target sequences, and are transcribed to form the stem portion of the “hairpin” structure of the shRNA.
Loop: This optimized sequence is transcribed to form the loop portion of the shRNA “hairpin” structure.
Terminator: Terminates transcription of the shRNA.
hPGK promoter: Human phosphoglycerate kinase 1 gene promoter. It drives the ubiquitous expression of the downstream marker gene.
Marker: A drug selection gene (such as neomycin resistance), a visually detectable gene (such as EGFP), or a dual-reporter gene (such as EGFP/Neo). This allows cells transduced with the vector to be selected and/or visualized.
WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element. It enhances viral RNA stability in packaging cells, leading to higher titer of packaged virus.
ΔU3/3' LTR: A truncated version of the HIV-1 3' long terminal repeat that deletes the U3 region. This leads to the self-inactivation of the promoter activity of the 5' LTR upon viral vector integration into the host genome (due to the fact that 3' LTR is copied onto 5' LTR during viral integration). The polyadenylation signal contained in ΔU3/3' LTR serves to terminates all upstream transcripts produced both during viral packaging and after viral integration into the host genome.
SV40 early pA: Simian virus 40 early polyadenylation signal. It further facilitates transcriptional termination after the 3' LTR during viral RNA transcription during packaging. This elevates the level of functional viral RNA in packaging cells, thus improving viral titer.
Ampicillin: Ampicillin resistance gene. It allows the plasmid to be maintained by ampicillin selection in E. coli.
pUC ori: pUC origin of replication. Plasmids carrying this origin exist in high copy numbers in E. coli.